Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?
Intensive chemotherapy has been the backbone of the treatment of acute myeloid leukemia (AML) for decades. However, an increase in novel targeted agents, which has been brought about in part by a deeper understanding of the genetic makeup of AML, has led to remission-inducing regimens that do not r...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2021-07-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/10343 |